Dr Brady J. Heward joins Ethics Talk to discuss his article, coauthored with Drs Amy M. Yule and Peter R. Jackson: “How Should Harm Reduction Strategies Differ for Adolescents and Adults?”
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Physicians treating adolescents need to give them the information to make intelligent and responsible decisions regarding sexual activity and reassure them of patient confidentiality.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
Psychiatrists face difficulties when deciding on treatment plans for patients who are not interested in receiving help or are lacking the capacity to make responsible decisions.
Psychiatrists face difficulties when deciding on treatment plans for patients who are not interested in receiving help or are lacking the capacity to make responsible decisions.
Psychiatrists face difficulties when deciding on treatment plans for patients who are not interested in receiving help or are lacking the capacity to make responsible decisions.